Contemporary use of cardiovascular risk reduction strategies in type 2 diabetes. Insights from the diabetes collaborative registry
- 8 May 2023
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 263, 104-111
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- AstraZeneca
This publication has 27 references indexed in Scilit:
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2019
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice projectEuropean Journal of Preventive Cardiology, 2017
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative RegistryDiabetes Care, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Microvascular and Macrovascular Complications of DiabetesClinical Diabetes, 2011
- Primary Prevention of Cardiovascular Diseases in People With Diabetes MellitusCirculation, 2007
- The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: The VA Cooperative Study in diabetesJournal of Diabetes and its Complications, 2006
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- Diabetes and Cardiovascular DiseaseCirculation, 1999